中文
菜单
  1. Home
  2. TMEA Platform
TMEA Platform
Industry Pain Points
Systemic toxicity is a key clinical pain point in anti-tumor drug development. Currently, the systemic distribution of various anti-tumor drugs is the primary cause of high toxicity and low efficacy. Both monotherapy and combination therapy are associated with significant toxicity, severely limiting their clinical application.
TMEA Platform Technology: Affinity’s Global first-in-class Innovation
This platform is designed to sense the tumor microenvironment and selectively deliver drugs, thereby reducing systemic and off-target toxicity while enhancing therapeutic efficacy.
Affinity’s TMEA Platform
Leveraging our proprietary Activatable Chemical Conjugate Linker and Functional Moiety, we transform traditional drugs into novel molecules that localize therapy to the tumor microenvironment. This platform enables the development of innovative therapies with global intellectual property rights.
  • Toxicity Dramatically Reduced
    Minimizes toxicity in healthy tissues and off-target organs
  • Enhanced Efficacy
    Expands the therapeutic window and extends drug half-life
  • Specific Linker Cleavage in Tumor Microenvironment Enables Full Pharmacological Activity Release
    High activation efficiency minimizes payload loss
  • Pan-Solid Tumor Targets
    Broad applicability across multiple solid tumor types
  • Low Immunogenicity
    Uses a chemical blocking group that eliminates or significantly reduces immunogenicity
  • Enables Combination Therapy
    Supports combination therapies with multiple innovative agents

Conventional Drugs
Affinity's Platform
Broad-Spectrum Platform
Based on the selective activation mechanism triggered by high expression of Legumain in the tumor microenvironment, each platform delivers reduced toxicity and enhanced efficacy, enabling a wide range of combination therapy options
  • TMEA-ALDC
  • TMEA-SMDC
  • TMEA-ADC
  • TMEA-TCE
  • TMEAbody
  • TMEAkine
Diversified Platforms

TMEA-XDC Pipeline
(Tumor Microenvironment Activated Conjugate Drug )
  • TMEA-ALDC: Facilitates the development of small-molecule conjugate drugs composed of three key components: the active drug, an activatable chemical linker, and a functional moiety.
  • TMEA-SMDC: In the design of certain conjugate small-molecule drugs, hydrophilic or actively targeted chemical groups are introduced as functional components.
  • TMEA-ADC: Offers multiple advantages over traditional antibody-drug conjugates (ADCs), including direct bystander effect, high activation efficiency, and dual tumor targeting specificity from both the activating enzyme and the antibody.
TMEA-IO Pipeline
(Tumor Microenvironment Activated Immunotherapy )
  • TMEA-TCE: T cell engagers (TCEs) are a novel class of immunotherapeutic agents that directly connect patients’ T cells to cancer cells, triggering cytotoxic responses to eliminate tumors.
  • TMEAboby: A chemical conjugation-based masked antibody platform that enables the construction of antibody-based therapeutics consisting of three key components: an active drug, an activatable chemical linker, and a functional moiety.
  • TMEAkine: A cytokine masking biological platform. This technology uses chemical conjugation to link the linker with a large masking molecule, thereby fully suppressing cytokine activity.